RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to the
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial – JAMA Editorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA Commentary: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay
The post RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Summary: Perioperative Management of Patients Taking Direct Oral Anticoagulants
- Summary: Community-Acquired Pneumonia
- RCT: Twice-Yearly Depemokimab Reduced Exacerbations in Severe Eosinophilic Asthma
- RCT: High-Intensity NPPV Reduced Criteria for Intubation in Acute COPD Exacerbations
- M-A | Routine anaerobic coverage for aspiration pneumonia: limited evidence of benefit
Laissez un commentaire
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.